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Abstract
Atelectasis was reported as a favorable prognostic sign of pulmonary carcinoma; however, the underlying mechanism in those
patients is not known. In this study, we aimed to investigate prospectively the potential impact of atelectasis and/or obstructive
pneumonitis (AO) on survival and the relation between atelectasis and some laboratory blood parameters. The study was
conducted on 87 advanced stage non-small cell lung cancer (NSCLC) patients. Clinical and laboratory parameters of patients
at ﬁrst presentation were recorded, and patients were divided into two groups according to the presence of AO in
thorax computed tomography (CT). Survival was calculated using Kaplan-Meier and univariate Cox’s regression analyses.
Laboratory parameters that mightbe relatedwith prolonged survival in atelectasis were compared using chi-square, Student’st,
and Mann-Whitney U tests. Of the patients, 54% had stage IV disease, and AO was detected in 48.3% of all cases. Overall
median survival was 13.2 months for all cases, 10.9 months for patients without AO, and 13.9 months for patients with AO
(P = 0.067). Survival was signiﬁcantly longer in stage III patients with AO (14.5 months versus 9.2 months, P = 0.032), but not
in stage IV patients. Patients with AO in stage III had signiﬁcantly lower platelet counts (P = 0.032) and blood sedimentation
rates than did those with no AO (P = 0.045). We concluded that atelectasis and/or obstructive pneumonitis was associated with
prolonged survival in locally advanced NSCLC. There was also a clear association between atelectasis and/or obstructive
pneumonitis and platelets and blood sedimentation rate.
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Introduction
Despite the emerging developments in the diagnosis
and treatment of lung cancer in recent years, it is still
the most lethal among all cancers. In order to under-
stand the pathobiology of lung cancer and also to
predict survival better, several prognostic factors have
been investigated in several studies (1). In a previous
retrospective study, we showed that atelectasis was
associated with prolonged survival (2). A recent study
by Dediu and co-workers also focused on the favor-
able prognostic signiﬁcance of atelectasis in non-small
cell lung cancer (NSCLC) and pointed out the role of
atelectasis in TNM staging (3). Indeed, atelectasis is
accepted as a negative prognostic sign in the previous
and recent TNM staging systems (4,5). Of the patients
with lung cancer, about one-third to one-quarter are
reported to have atelectasis at ﬁrst presentation (2,6).
In this study we aimed to investigate prospectively
the potential impact of atelectasis and/or obstructive
pneumonitis on survival and to investigate possible
underlying conditions that might be related to
prolonged survival in non-small cell lung cancer.
Materials and methods
Study design
This was a prospective observational study evaluating
the role of atelectasis on survival and some related
Correspondence: Associate Professor Yilmaz Bulbul, Karadeniz Technical University, School of Medicine, Department of Chest Diseases, 61080, Trabzon,
Turkey. Fax: +90 462 325 70 31. E-mail: bulbulyilmaz@yahoo.com
(Received 22 December 2009; accepted 10 February 2010)
ISSN 0300-9734 print/ISSN 2000-1967 online   2010 Informa UK Ltd. (Informa Healthcare, Taylor & Francis AS)
DOI: 10.3109/03009731003695624underlying conditions in NSCLC patients. The study
was conducted at Farabi Hospital, a tertiary care
hospital at Karadeniz Technical University, Turkey,
and was approved by the local ethics committee.
Study setting and population
All patients with NSCLC diagnosed and followed up
in the chest clinic of Farabi Hospital between April
2006 and May 2008 and who met the inclusion
criteria were enrolled in the study. Patients who gave
writteninformedconsentandhadaperformancestatus
between 0–2 according to ECOG (European Cooper-
ative Oncology Group) were included. Patients who
had resectable lung cancer, who received prior
chemotherapy or radiotherapy, who had no deﬁnitive
histologic diagnosis, who had bad performance status
(ECOG 3 or 4), and who had a disease other than lung
cancer that might affect survival or the results of blood
tests, such as liver cirrhosis, severe chronic obstructive
pulmonary disease (COPD) or cardiac insufﬁciency,
concomitant malignancy, etc., were excluded.
Patients were staged according to the TNM system.
As part of routine clinical evaluation in our unit,
staging was done using thorax, abdomen, and cranial
tomography and bone scanning. Routine blood tests
(biochemistry and complete blood counts) were done
in all cases before each cycle of chemotherapy. In the
treatment of patients, platinum-based treatment
regimes (docetaxel, vinorelbine, or gemcitabine)
were used every 3 weeks. Evaluation of treatment
responses was carried out after three cycles of che-
motherapy using Response Evaluation Criteria In
Solid Tumors (RECIST) criteria (7). Following three
cycles of therapy, external radiotherapy with a total
dose of 63 Gy in 35 fractions was applied in locally
advanced cases. Diagnosis of atelectasis and/or
obstructive pneumonitis was conﬁrmed using thorax
computed tomography (CT) on ﬁrst presentation.
Blood test results obtained before the ﬁrst cycle of
chemotherapy were used for the comparison between
patients with and without atelectasis.
Statistical analysis
Survival was studied from the date of histopathologic
diagnosis to the last contact with the patient. Survival
curves were calculated using the Kaplan-Meier
method, and statistical comparisons were performed
by log-rank test. The relationship between atelectasis
and survival was examined using univariate Cox’s
regression analysis. For the comparison of ﬁndings
between patient subgroups, the chi-square test was
used for quantitative data and Mann Whitney U or
Student’s t tests were used for qualitative data, and
P-values <0.05 were considered to be signiﬁcant.
Results
Duringthestudyperiod,155lungcancerpatientswere
diagnosed and followed up in our clinic, and among
thosepatients87NSCLCpatientswereincludedinthe
study; 47 with stage IV disease, 40 with locally
advanced stage III disease (8 patients with stage
IIIA, 32 patients with stage IIIB). Of the excluded
patients, 28 had small cell lung carcinoma, 19 had
resectable lung cancer, 13 had bad performance status
(ECOG >2), and 8 had not given signed informed
consent or had concomitant diseases, etc. Of the cases
included,theaverageagewas 64.95±10.56years,and
only 5 were women. Of all patients, 32 (36.8%) had
only atelectasis (2 total, 16 lobar, and 14 segmentary)
and 42 (48.3%) had atelectasis and obstructive pneu-
monia. Demographic characteristics of patients with
and without atelectasis are given in Table I.
Relationship between atelectasis and survival
Overall median survival was 13.2 months (range 0.2–
32.0 months) for all cases, 10.9 months for patients
with no atelectasis, and 13.9 months for patients with
atelectasis (P = 0.067). When patients are discri-
minated as local and metastatic disease, survival
was found to be 14.5 months with atelectasis in
locally advanced patients and 9.2 months without
atelectasis (P = 0.032). In univariate Cox’s regression
analysis, atelectasis was also associated with prolonged
survival (odds ratio (OR) 2.43, 95% conﬁdence inter-
val (CI) 1.06–5.58, P = 0.037). However, in metastatic
patients, survival was not different between atelectatic
and non-atelectatic patients (Table II).
Subgroup analysis of patients with locally advanced
stage showed that survival was longer in stage IIIB
patients with atelectasis (1-year survival rates
and median survival in atelectatic patients were
72.2% and 13.93 months; in non-atelectatic patients
they were 35.8% and 9.26 months, respectively,
P = 0.044). However, because there were only
8 patients in stage IIIA, survival curves could not
be calculated in this subgroup.
Blood tests in patients with/without atelectasis
When locally advanced patients were taken into
consideration, we found no difference in C-reactive
protein (CRP), lactate dehydrogenase, alkaline
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counts, and lymphocyte counts in atelectatic and
non-atelectatic patients (data not shown). However,
platelet counts and blood sedimentation rates were
signiﬁcantly lower in patients with atelectasis. Platelet
counts were 322.100 ± 90.100 cells/mL in the atelec-
tatic group and 384.600 ± 80.100 cells/mL in the
non-atelectatic group (P = 0.032). Blood sedimenta-
tion rates were 39 ± 17 mm/h in atelectatic and
53 ± 23 mm/h in non-atelectatic patients (P = 0.045).
Discussion
The results of our study show that atelectasis was
associated with prolonged survival, especially in
locally advanced lung cancer. This ﬁnding was in
accordance with two previous studies. In the ﬁrst
study, which included both small cell lung cancer
(SCLC) and NSCLC patients, it was shown that
atelectasis was associated with a prolonged survival
especially in advanced stage lung cancer patients (2).
Table I. Demographic characteristics of patients with NSCLC.
Patients with
AO (n = 42) No AO (n = 45) P
Age 64.09 ± 10.75 65.77 ± 10.44 0.465
Sex (Female) 3 (7.1%) 2 (4.4%) 0.669
Tumor size
T1–2 4 (9.5%) 4 (8.9%) NS
T3 9 (21.5%) 9 (20.0%)
T4 29 (69.0%) 32 (71.1%)
Lymph node involvement
N0–1 7 (16.7%) 11 (24.5%) NS
N2 30 (71.4%) 22 (48.9%)
N3 5 (11.9%) 12 (26.6%)
Metastasis (M1) 25 (59.5%) 22 (48.9%) 0.320
Cranial metastasis 5/42 (11.9%) 3/45 (6.8%) 0.479
Chemotherapy regimen (Platinum+)
Docetaxel 28 (66.7%) 29 (64.4%) NS
Gemcitabine 8 (19.0%) 7 (15.6%)
Vinorelbine 4 (9.5%) 5 (11.1%)
Other 2 (4.8%) 4 (8.9%)
Performance status (ECOG)
0 11 (26.2%) 11 (24.5%) NS
1 28 (66.7%) 29 (64.4%)
2 3 (7.1%) 5 (11.1%)
NSCLC: Non-small cell lung carcinoma, AO: Atelectasis and/or obstructive pneumonitis, ECOG: Eastern Cooperative Oncology Group.
Table II. One-year survival rates and median survival in NSCLC patients with and without atelectasis.
Patients with AO Patients with no AO
P
1-year
survival (%)
MST
(months)
Range
(months)
1-year
survival (%)
MST
(months)
Range
(months)
Locally advanced cases 67.2 14.5 1.9–25.0 40.0 9.8 0.8–17.6 0.032
Stage IIIB 72.2 13.9 9.2–18.7 35.8 9.3 5.4–13.1 0.044
Metastatic cases 60.2 13.3 0.7–32.0 52.5 12.9 0.2–19.0 0.621
All cases 63.2 13.9 0.7–32.0 44.4 11.0 0.2–19.0 0.067
NSCLC: Non-small cell lung carcinoma, AO: Atelectasis and/or obstructive pneumonitis, MST: Median survival time.
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patients with atelectasis had a favorable prognosis
mainly in locally advanced NSCLC (3). In contrast
to these data, only Coen at al. reported that survival
was not different in patients with atelectasis (8).
The effect of atelectasis was also investigated in
stage IB tumors; however, it has been shown that
presence of atelectasis in those patients has no impact
on survival (9,10).
Atelectasis is a common condition with lung can-
cer. In our study, 36.8% of patients had atelectasis,
and 48.3% had atelectasis and obstructive pneumo-
nitis. Those results are in accordance with previous
ﬁndings (2,6,11). In pulmonary carcinoma, atelecta-
sis is usually developed due to endobronchial obstruc-
tion but less frequently due to compression of tumor
or pleural effusion. It is known that vascular shunts
develop in atelectatic areas (12). In our previous
study, we had pointed out that prolonged survival
in atelectasis might be related to decreased intratu-
moral blood ﬂow and nutrition due to shunts in the
neighboring atelectatic area (2). Actually, lower levels
of platelet counts in patients with atelectasis might
support this hypothesis. The relation between survival
and platelets was studied in several studies, and
thrombocytosis was reported to be related to poor
prognosis (13–17). The mechanism underlying
thrombocytosis is unclear; however, it is speculated
to be related to the stimulation of bone-marrow
by the cytokines (Interleukin (IL)-1, IL-6, and
Macrophage-Colony Stimulating Factor (M-CSF))
secreted from cancer cells (18,19). If this is correct,
decreased blood supply and nutrition of tumor due
to atelectasis and shunt effects may decrease the
release of these cytokines from cancer cells. In addi-
tion, patients without atelectasis had increased blood
sedimentation rates than did atelectatic patients. The
increased sedimentation rate in non-atelectatic
patients may be related to increased ﬁbrinogen syn-
thesis by well nourished cancer cells. Sahni et al.
reported that ﬁbrinogen synthesized from cancer
cells may promote the growth of lung and prostate
cancer cells through interaction with ﬁbroblast
growth factor-2 (FGF-2) (20).
Another hypothesis that might relate to prolonged
survival is the susceptibly of infection and the altered
immunity in atelectasis. Nguyen at al. reported that
naturalkillerandlectin-dependentcell-mediatedcyto-
toxicityactivitiesinperipheralbloodlymphocyteswere
signiﬁcantly increased in animals with right lower lobe
atelectasis(21).Theyalsoreportedthatatelectasiswas
associatedwithaninﬂuxofpolymorphonuclearleuko-
cytesintothebronchoalveolarcompartment.However,
in our study, in locally advanced cases, we found no
correlationbetweenatelectasisandCRP,anon-speciﬁc
marker of systemic inﬂammation. In addition, there
wasnocorrelationbetweenatelectasisandwhiteblood
cell counts and lymphocytes. The negative prognostic
signiﬁcance of high CRP levels and peripheral blood
leukocyte count in pulmonary carcinoma has been
reported in some prior studies (18,19,22,23).
Dediu et al. claimed that prolonged survival in
atelectasis was associated with the speciﬁc growing
pattern of tumor (3). According to this hypothesis,
patients with atelectasis present earlier and receive
earlierdiagnosisduetoconcentricgrowthofthetumor.
However,wethink thesimilarityofT,N,andMstatus
between patients with and without atelectasis on ﬁrst
admission does not support this hypothesis.
We acknowledge some restrictions of this study.
First of all, the number of patients included in the
study is limited. Also, the effect of atelectasis and
shunts on the nutrition of tumor tissue would be
better shown if we had measured some cytokines
and hormones secreted by the cancer cells. Lastly,
we did not consider patients who developed atelec-
tasis after the ﬁrst presentation, i.e. during follow-up.
Because of these limitations, a complete analysis of all
factors that may be related to atelectasis and prognosis
should be considered in a prospective study.
In conclusion, our study has shown that atelectasis
and/or obstructive pneumonitis was associated with
prolonged survival in locally advanced NSCLC cases.
We also found a signiﬁcant correlation between atel-
ectasis and platelets and blood sedimentation rate.
Although the relationship between atelectasis and
survival was in accordance with two previous studies,
we think more comprehensive studies are needed to
reach a ﬁnal judgment on the effect of atelectasis on
survival.
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